Advertisement

Breast Cancer Research and Treatment

, Volume 25, Issue 1, pp 29–35 | Cite as

Comparative effect of embryonic mouse fibroblasts (Balb/c-3T3) on the proliferation of hormone-dependent (T-47D) and hormone-independent (MDA-MB-231) human breast cancer cell lines

  • Gerard Chetrite
  • Laurence Delalonde
  • Jorge R. Pasqualini
Report

Summary

The effects of cellular extracts (CE) and conditioned medium (CM) of embryonic mouse BALB/c-3T3 (clone A 31) cells on the proliferation and DNA content of hormone-dependent T-47D and hormone-independent MDA-MB-231 breast cancer cell lines were explored. After 6 days of culture, CE and CM provoke an intense proliferative effect in T-47D cells which correlates with DNA content. In contrast, in the MDA-MB-231 cells a significant inhibitory effect was observed. For both CE and CM the action was dose-dependent. In the T-47D cells, the CM can abolish the inhibitory effect provoked by the potent antiestrogen ICI 164,384. It is concluded that mouse embryonic BALB/c-3T3 cells contain factors which can stimulate or inhibit the growth of human mammary cancer cells.

Key words

growth factors antiestrogens embryonic cells breast cancer cells progesterone receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pasqualini JR: Growth factors during fetal life: physicochemical properties, biological role, and receptors. In: Pasqualini JR, Scholler R (eds) Hormones and Pathophysiology. Marcel Dekker Inc., New York, 1992, pp 673–714Google Scholar
  2. 2.
    Dickson RB: Stimulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Molec Biol 37: 795–803, 1990Google Scholar
  3. 3.
    Lippman ME, Dickson RB, Bates S, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelmann EP: Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7: 59–70, 1986Google Scholar
  4. 4.
    Wakeling AE, Bowler J: Novel antioestrogens without partial agonist activity. J Steroid Biochem 31: 645–653, 1988Google Scholar
  5. 5.
    Burton K: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315–323, 1956Google Scholar
  6. 6.
    Korenman SG: Radio-ligand binding assay of specific estrogens using a soluble uterine macromolecule. J Clin Endocr Metab 28: 127–130, 1968Google Scholar
  7. 7.
    Pasqualini JR, Nguyen B-L: Progesterone receptors in the fetal uterus and ovary of the guinea pig: evolution during fetal development and induction and stimulation in estradiol-primed animals. Endocrinology 106: 1160–1165, 1980Google Scholar
  8. 8.
    Pasqualini JR, Gelly C: Biological response of the antiestrogen ICI 164,384 in human hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett 50: 133–139, 1990Google Scholar
  9. 9.
    Cole MP, Jones CTA, Todd IDH: A new anti-estrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 25: 270–275, 1971Google Scholar
  10. 10.
    Ward HWC: Antioestrogenic therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13–14, 1973Google Scholar
  11. 11.
    Mouridsen H, Palshof T, Patterson J, Battersby, L: Tamoxifen in advanced breast cancer. Cancer Treat Rep 5: 131–141, 1978Google Scholar
  12. 12.
    Wakeling AE: Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 34: 183–188, 1989Google Scholar
  13. 13.
    Horwitz KB, Wei LL, Sedlacek SM, d'Arville CN: Progestin action and progesterone receptor structure in human breast cancer: a review. In: Greep RO (ed) Recent Progress in Hormone Research, Vol 41. Academic Press, New York, 1985, pp 249–316Google Scholar
  14. 14.
    Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ: Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15: 659–670, 1979Google Scholar
  15. 15.
    Sherman MR, Corvol PL, O'Malley BW: Progesterone-binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. J Biol Chem 245: 6085–6096, 1970Google Scholar
  16. 16.
    Feil PD, Glasser SR, Toft DO, O'Malley BW: Progesterone binding in the mouse and rat uterus. Endocrinology 91: 738–746, 1972Google Scholar
  17. 17.
    Pasqualini JR, Sumida C, Giambiagi N: Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem 31: 613–643, 1988Google Scholar
  18. 18.
    Peyrat J-P, Bonneterre J, Hondermarck H, Hecquet B, Adenis A, Louchez MM, Lefebvre J, Boilly B, Demaille A: Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer. J Steroid Biochem Molec Biol 43: 87–94, 1992Google Scholar
  19. 19.
    Moses HL, Yang EY, Pietenpol JA: TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63: 245–247, 1990Google Scholar
  20. 20.
    Gelb DE, Rosier RN, Puzas JE: The production of transforming growth factor-β by chick growth plate chondrocytes in short term monolayer culture. Endocrinology 127: 1941–1947, 1990Google Scholar
  21. 21.
    Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE: Coordinated regulation of apoptosis and cell proliferation by transforming growth factor-β1 in cultured uterine epithelial cells. Cell Biol 88: 3412–3415, 1991Google Scholar
  22. 22.
    Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK: Transforming growth factor-β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898–3904, 1988Google Scholar
  23. 23.
    Miller MA, Katzenellenbogen BS: Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res 43: 3094–3100, 1983Google Scholar
  24. 24.
    Goustin AS, Leof EB, Shipley GD, Moses HL: Growth factors and cancer. Cancer Res 46: 1015–1029, 1986Google Scholar
  25. 25.
    Koga M, Sutherland RL: Epidermal growth factor partially reverses the inhibitory effects of antiestrogens on T-47D human breast cancer cell growth. Biochem Biophys Res Commun 146: 739–745, 1987Google Scholar
  26. 26.
    Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987Google Scholar
  27. 27.
    Headon DR, Allan G: Steroid hormones and growth factor receptors. Biochem Soc Trans 17: 598–599, 1989Google Scholar
  28. 28.
    Chetrite G, Pasqualini JR: Biological responses of ICI 164,384 and other anti-estrogens in vaginal and uterine cells of fetal guinea pig in culture. Acta Endocr (Copenh)125: 401–408, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Gerard Chetrite
    • 1
  • Laurence Delalonde
    • 1
  • Jorge R. Pasqualini
    • 1
  1. 1.Foundation for Hormone ResearchC.N.R.S. Steroid Hormone Research UnitParisFrance

Personalised recommendations